Navigation Links
Mitochondria play role in pathogenesis of AD and estrogen-induced neuroprotection
Date:4/5/2008

s, or programmed cell death, of neurons of the brain;

  • and protection of neurons from mitochondrial toxins, which can induce further mitochondrial dysfunction and cell death.

    Dr. Brinton and her research team currently are validating the energy-production levels of mitochondria as a biomarker that could detect the presence of Alzheimers in the earliest stages, when the neurodegenerative process might be stopped or slowed or therapeutics be more effective. They believe this new information on how estrogen regulates mitochondrial function also sheds light on how to develop a new generation of effective Alzheimer therapeutics. Dr. Brinton currently is developing new, brain specific molecules that promote neurological defense against Alzheimers, using similar mechanisms as estrogen, but without estrogens negative side effects.


    '/>"/>


  • Contact: Sylvia Wrobel
    ebpress@gmail.com
    770-722-1055
    Federation of American Societies for Experimental Biology
    Source:Eurekalert

    Page: 1 2

    Related medicine news :

    1. Study looks at mitochondrial variation in sperm traits and sperm competitive ability
    2. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
    3. Mitochondria send death signal to cardiac cells, study shows
    4. Agent orange chemical, dioxin, attacks the mitochondria to cause cancer, says Penn research team
    5. Mitochondrial bottleneck cracked
    6. In silico modeling helps predict severity of mitochondrial disease
    7. Single Mutation in Mitochondrial DNA Weakens Heart, Muscles
    8. United Mitochondrial Disease Foundation Statement on Vaccines, Autism and Mitochondrial Disease
    9. MITOCHONDRIAL DYSFUNCTION, VACCINES AND AUTISM: 1 in 50 Children Could Be at Risk
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/21/2015)... (PRWEB) April 21, 2015 The PracticeMatch ... from 5:00 to 8:00 pm at the William and Ida ... Hill, NC 27599. More than 50 hospitals, clinics and groups ... All specialties will be represented. Attendees will enjoy free hors ... Career Fairs for PracticeMatch says “Chapel Hill is ...
    (Date:4/21/2015)... United Benefit Advisors (UBA), the nation’s ... to welcome Power Kunkle Benefits Consulting as its ... Jeff Power have been committed to providing the ... more than 450 clients. For Power Kunkle Benefits ... stewardship, ethical consulting, and measurable results. , ...
    (Date:4/21/2015)... (PRWEB) April 21, 2015 Atlantic ... the launch of Medicare-Medicaid Dual Eligibles Database, a ... on care provided to the more than 9 ... account for more than $300 billion in annual ... – the same team that also creates the ...
    (Date:4/21/2015)... Nashville, Tenn. – Radsource, a leader ... Archiving and Communication Systems (PACS), has expanded its ... the first quarter of 2015. , Kentucky Breast ... and Lowcountry Orthopaedics & Sports Medicine (Charleston, SC) ... services. Mt. San Rafael Hospital (Trinidad, CO) will ...
    (Date:4/21/2015)... Timonium, Maryland (PRWEB) April 21, 2015 eSight ... who are legally blind to see and, on Tuesday, May ... (LVS of MD & VA) will host an unveiling ... Timonium, MD office. LVS of MD & VA will be ... eyewear. A limited number of individual patient demonstrations will be ...
    Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 2Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 3Health News:Power Kunkle Benefits Consulting Is the Latest Partner Firm To Join United Benefit Advisors 2Health News:New AIS Database Tracks All Programs, Plans Serving the Dual-Eligible Community 2Health News:Radsource Adds 4 ProtonPACS Clients in 1st Quarter 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 3
    ... Steps To Serve Your Champagne This Holiday With Style And ... Ease - And Most Importantly ... ,There,s nothing that brings a little sparkle to your holiday ... Americans will,consume more than 900 million glasses of champagne this ...
    ... Calif., Dec. 21 Pharmacyclics,Inc. (Nasdaq: PCYC ) ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of non-small cell lung cancer (NSCLC) patients ... combination with whole brain,radiation therapy (WBRT) was filed with ...
    ... 21 Biodel Inc. (Nasdaq:,BIOD) today announced that Dr. ... corporate update at the 26th Annual JPMorgan Healthcare,Conference on ... The JPMorgan Healthcare Conference will be held January ... Francisco, California., Interested parties may access a link ...
    ... Center receives shipment milestone - expanding, their depth ... SET technologies, IRVINE, Calif., Dec. 21 ... Read-Through Motion and Low,Perfusion pulse oximetry, today announced ... bedside pulse oximeter (excluding hand-held units) to,Alta Bates ...
    ... Contest Urges Young People to Promote Home,Safety, ... has named the winners of its 2008 National ... States Environmental Protection,Agency. First-place winner is Sara Garcia, ... Science in Hollywood, Florida; second-place winner is,Daniel Carr, ...
    ... Ireland Cancer Center of University Hospitals Case Medical Center, in ... the Cancer Research Network, found that the majority of older ... the standard of treatment five years of daily oral ... the February issue of Journal of Clinical Oncology and released ...
    Cached Medicine News:Health News:Five Steps to Pop the Cork - Not Your Eye Out 2Health News:Five Steps to Pop the Cork - Not Your Eye Out 3Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 2Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 3Health News:Biodel Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 7th, 2008 2Health News:Biodel Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 7th, 2008 3Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 2Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 3Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 4Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 5Health News:National Safety Council Names Winners of Radon Poster Contest 2Health News:Ireland Cancer Center researcher finds standard treatment for breast cancer not followed 2
    (Date:4/21/2015)... April 21, 2015  Legal-Bay LLC, The Lawsuit ... Boehringer Ingelheim Pharmaceuticals, is seeking FDA approval for ... According to PBR, Boehringer submitted a supplemental new ... that Pradaxa will be approved for the prophylaxis ... (PE) for patients who have undergone a primary ...
    (Date:4/20/2015)... , April 20, 2015 Research published today ... of Sciences (PNAS) demonstrates that technology invented ... Casey Eye Institute can improve the ... Optical coherence tomography (OCT) angiography could largely replace ... diseases. OHSU researchers found that OCT ...
    (Date:4/20/2015)... BILLERICA, Mass. , April 20, 2015 /PRNewswire/ ... tools for cell metabolism research, introduces the XFp ... a unique real-time assay on live cells that ... one-hour test measures both the mitochondrial and glycolytic ... values with metabolic activity under stressed conditions, induced ...
    Breaking Medicine Technology:Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 2Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 3Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5New XFp Cell Energy Phenotype Test Determines Metabolic Potential 2New XFp Cell Energy Phenotype Test Determines Metabolic Potential 3
    ... As previously announced, primary endpoint not met; ... with ERBITUX,-, NEW YORK, April 16, 2007 ... Company today,announced detailed results from the EPIC ... trial - comparing ERBITUX(R),(Cetuximab) plus irinotecan to ...
    ... WIRE)--Apr 17, 2007 - Curis, Inc.,(NASDAQ:CRIS), a ... primarily for cancer treatment, today announced that ... the 98th Annual Meeting,of the American Association ... also disclosed that its April 2005 discovery,collaboration ...
    Cached Medicine Technology:Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 2Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 3Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 4
    Aluminum english and metric ruler. 1 3/8 inche wide....
    At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
    Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
    Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
    Medicine Products: